ǰÑÔ
°¢¶û´Äº£Ä¬²¡(Alzheimer's disease,AD)ÓÖ³ÆÍíÄêÐÔ³Õ´ô£¬ÊÇ×î³£¼ûµÄ³Õ´ôÀàÐÍ£¬Õ¼ËùÓгմô²¡ÀýµÄ2/3¡£ÆäÁÙ´²ÌØÕ÷Ϊ¾ÙÐÐÐÔ³Õ´ô£¬ÌåÏÖΪӰÏó¼õÍË¡¢ÈÏÖªÕϰºÍÈ˸ñ¸Ä±äµÈ¡£Ö÷Òª²¡ÀíÌØÕ÷Ϊ´óÄÔÆ¤Öʺͺ£ÂíÇø·ºÆðÍíÄê°ß(senile plaque,SP)¡¢Éñ¾ÔªÄÚÉñ¾ÔÏËά²ø½á(neurofibrillary tangle, NFT£©ºÍÉñ¾Ñ×Ö¢¡£¾Ý½üÄêµÄ×ÊÁÏͳ¼Æ£¬È«ÌìÏÂÓÐ3500ÍòAD»¼Õß¡£ÔÚÖйú£¬AD»¼ÕßÒÔÿÄê30¶àÍòµÝÔö£¬Õâ¶ÔÒѾ½øÈëÍíÄ껯Éç»áµÄÖйúÕþ¸®ºÍÉç»á¼°Ð¡ÎÒ˽¼Ò¶øÑÔ¶¼´øÀ´¼«Öصļ縺¡£×èÖ¹ÏÖÔÚ£¬Õë¶ÔADÉÐÎÞÓÐÓõÄÖÎÓúÒªÁ죬ΪÁËÔöÇ¿ÁÙ´²Ò½Ñ§×ª»¯Ñо¿ÒÔ¼°ÁÙ´²Ç°Ò©Îïɸѡ£¬ÎÒÃÇÆÈÇÐÐèÒªÉú³¤ºÍ¿ª·¢Ïà¹ØµÄ¶¯ÎïÄ£×Ó¡£
AD¶¯ÎïÄ£×ÓÊÇÒÔʵÑ鶯ÎïÄ£ÄâAD»¼ÕßÄÔ×éÖ¯µÄ²¡Àíת±ä¼°ÐÐÎªÌØÕ÷¡£ÏÖÔÚAD¶¯ÎïÄ£×Ó´ó¶àÖ»ÄÜÄ£ÄâADijЩ²¡±ä»òÕßÖ¢×´£¬ÍêÈ«ÇкÏÈËÀàAD²¡±äµÄ¶¯ÎïÄ£×ÓÉÐδÎÊÊÀ¡£¿ÉÊÇ£¬Ëæ×Å·Ö×ÓÉñ¾ÉúÎïѧµÄÉú³¤£¬Ò»Ö±ÓиüΪϸÄåµÄ¸üÇкÏAD²¡±ä±¬·¢Éú³¤Àú³ÌµÄ¶¯ÎïÄ£×ÓÑÐÖÆ³öÀ´£¬Îª½øÒ»²½Ã÷È·ADµÄ·¢²¡»úÖÆÊ©Õ¹Ö÷ÒªµÄ×÷Óá£
´ÓADÄ£×ÓÖÆ×÷ºÍÓ¦ÓÃÀúÊ·À´¿´£¬ÒÔ»ùÒò¹¤³ÌÊÖÒÕÖÆ×÷µÄAD¶¯ÎïÄ£×Ó»ñµÃÔ½À´Ô½ÆÕ±éµÄÓ¦Ó㬠¶øÒÔ»¯Ñ§¶¾Îï»òÎïÀíËðÉËÌØ¶¨²¿Î»µÄADÔìÄ£·½·¨ÓÉÓÚ±£´æ°Ðλ²»×¼È·£¬Îó²î´ó£¬Ó¦ÓÃÔ½À´Ô½ÉÙ¡£Òò´Ë£¬ÔÚADµÄ¶¯ÎïÄ£×ÓÖУ¬ÎÒÃǽ«×ÅÖØÏÈÈÝÒÔ»ùÒò¹¤³ÌÊÖÒÕÖÆ×÷µÄ»ùÒòÐÞÊÎAD¶¯ÎïÄ£×Ó¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÖÐÊàÉñ¾µ¨¼îÄÜϵͳ»îÐÔÓëÈ˵ÄѧϰӰÏóÒÔ¼°ÈÏÖª¹¦Ð§Ç×½üÏà¹Ø¡£»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾Ôª¡¢º£ÂíºÍ´óÄÔÆ¤Öʼ°ÆäÖ®¼äµÄͨ·£¬ÊÇѧϰӰÏó¹¦Ð§µÄÖ÷Òª½á¹¹»ù´¡¡£AD»¼Õß»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾Ôª´ó×ÚËðÉ˺ÍéæÃü£¬ÒÒõ£µ¨¼îµÄºÏ³É¡¢ÉãÈ¡ÄÜÁ¦ÒÔ¼°µ¨¼îÒÒõ£×ªÒÆÃ¸µÄ»îÐÔ¶¼ÏÔÖøÏ½µ£¬ ÕâЩ²¡±äÓëAD»¼ÕßÈÏÖª¹¦Ð§µÄË𺦳ÊÕýÏà¹Ø¡£Í¨¹ýÖÖÖÖÒªÁìÆÆË𵨼îÄÜÉñ¾ÏµÍ³µÄ¹¦Ð§£¬ÖÆ×÷AD¶¯ÎïÄ£×Ó¡£
¡¾Ä£×ÓÒªÁìºÍÄ£×ÓÌØµã¡¿£º
1. ñ·Â¡º£ÂíÉ¡ËðÉËÄ£×Ó Í¨¹ýÁ¢Ì嶨λºÍ²ÎÕÕͼÆ×£¬ÊÖÊõÇжÏñ·Â¡º£ÂíÉ¡¡£Êõºó¶¯Îï·ºÆðѧϰӰÏó¹¦Ð§Õϰ£¬µ«Î´·ºÆðAβºÍNFT²¡±ä²¢ÇÒËðÉ˹æÄ£´ó£¬ÒѾºÜÉÙ½ÓÄÉ¡£
2. ÐË·ÜÐÔ°±»ùËáËðÉËÄ£×Ó ½«ÐË·ÜÐÔ°±»ùËáÈç¶ì¸àÞ¦°±Ëá¡¢º£ÈËËá»òʹ¾ý×ÓËáµÈ×¢È붯ÎïµÄ»ùµ×MeynertºË½¨ÉèADÄ£×Ó¡£ÓÉÓÚ»ùµ×µ¨¼îÄÜÉñ¾ÔªÓë·Çµ¨¼îÄÜÉñ¾ÔªÓн»Ö¯ÐÔÂþÑÜ£¬ÒÔÊÇÕâЩ¶¾ËضԵ¨¼îÄÜÉñ¾ÔªµÄÑ¡ÔñÐÔÆÕ±é½Ï²î£¬ºÜÄÑɨ³ý·Çµ¨¼îÄÜÉñ¾ÔªËðÉ˺ó´øÀ´µÄ×ÌÈÅÒòËØ¡£
3. ÃâÒß¶¾ËØËðÉËÄ£×Ó ÃâÒß¶¾ËØ192-IgGSaporinÄܹ»Ñ¡ÔñÐÔÆÆËð»ùµ×ǰÄÔµ¨¼îÄÜϸ°û£¬¶ø²»Ó°ÏìÆäËû»¯Ñ§ÊôÐÔµÄϸ°û¡£´óÊóË«²à²àÄÔÊÒ×¢Éä192-lgG-Saporinºó£¬ÄÚ²à¸ôºËµ¨¼î¿áøÑôÐÔµÄÉñ¾Ôª´ó´ó¶¼É¥Ê§£¬Ñ§Ï°Ó°ÏóÄÜÁ¦Ä£×ÓϽµ¡£¿ÉÊÇ£¬µ¨¼îÄÜÉñ¾ÔªÍùÍùÒ²º¬ÓÐÆäËû»¯Ñ§ÊôÐÔ£¬ÒÔÊǸÃÄ£×ÓºÜÄÑ×èÖ¹¾ßÓÐË«ÖØ»ò¶àÖØ»¯Ñ§ÊôÐÔµÄÉñ¾ÔªËðÉË ºó´øÀ´µÄ×ÌÈÅÓ°Ïì¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
´ËÀàÄ£×ÓÖ÷ÒªÓÃÓÚÑо¿£º»ùµ×ǰÄÔµ¨¼îÄÜϵͳËðÉËÓëADµÄ¹ØÏµ£»Ä⵨¼îÄÜÒ©ÎïÖÎÁÆADµÄÒ©ÎïɸѡºÍÁÆÐ§ÆÀ¼Û£»Éñı»®ÑøÒò×ÓÄÔÊÒ×¢ÉäÖÎÁÆAD£»»ùÒòÐÞÊÎË¢ÐÂÅßÌ¥µ¨¼îÄÜϸ°û²¢¾ÙÐÐÄÔÄÚÒÆÖ²ÖÎÁÆ¡£
²Î¿¼ÎÄÏ×£º
1.Andrä K, Abramowski D, Du.ke M, et al. Expression of APP in transgenic mice:a comparison of neuron-specific promoters. Neurobiol Aging, 1996, 17 (2):183-190
2.Chishti MA, Yang DS, Janus C, et al. EarJy-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of arnyloid precursor protein 695. J Biol Chem,2001,276(24):21562-21570
3.Games D,Adams D,Alessandrini R,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyl,0id precursor protein. Nature, 1995,373(6514): 523-527
4.Hsiao K,Chapman P,Nilsen S,et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996,274(5284):99-102
5.Oddo S,Caccamo A,Shepherd JD,et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39 (3):409-421
6.Perez M, Ri be E, Rubio A, el al. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience, 2005, 130 (2):339-347
7.Rhein V, Song X, Wiesner A, et al. Arnyloid-beta and tau synergistically impair the oxidative phosphorylation ystem in lriple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA,2009, 106 (47):20057-20062